ArticleEthiopian journal of health sciences2025
SGCE Myoclonus Dystonia: A Case Report.
Article in Ethiopian journal of health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SGCE myoclonus dystonia is a rare genetic movement disorder caused by mutations in the SGCE gene. It typically presents in childhood and is characterized by myoclonus and dystonia. The inheritance pattern is autosomal dominant with maternal imprinting. Patients often exhibit associated psychiatric disorders, although cognitive function remains intact. Treatment includes antiseizure medications for myoclonus and anticholinergic agents or botulinum toxin for dystonia. Deep brain stimulation may be used for severe cases. Case Presentation: We present the case of a 2-year-old female who developed dystonia in her lower limbs over eight months, followed by myoclonus affecting her trunk and extremities. She met her developmental milestones and had no family history of similar conditions. Genetic testing revealed a pathogenic variant of the SGCE gene. She showed improvement with clonazepam. Conclusion: Myoclonus dystonia should be considered in patients presenting with early-onset myoclonus and dystonia. Genetic testing can confirm the diagnosis by identifying SGCE gene mutations. We hope this case increases awareness of SGCE myoclonus dystonia and encourages further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.